| Unique ID issued by UMIN | UMIN000049587 |
|---|---|
| Receipt number | R000056425 |
| Scientific Title | A dose-ranging study on mitochondrial function as an indicator of exercise performance after ingestion of test foods in healthy adult men. |
| Date of disclosure of the study information | 2022/11/23 |
| Last modified on | 2022/11/22 17:03:51 |
A dose-ranging study on mitochondrial function as an indicator of exercise performance after ingestion of test foods in healthy adult men.
Dose-ranging study of test foods
A dose-ranging study on mitochondrial function as an indicator of exercise performance after ingestion of test foods in healthy adult men.
Dose-ranging study of test foods
| Japan |
Healthy Volunteers
| Adult |
Others
NO
To examine the efficacy and effective dose of ingestion of food extracts on mitochondrial function.
Efficacy
oxygen utilization efficiency and maximal oxygen uptake
respiratory rate, ventilation threshold, exercise duration, blood concentration, and urinary excretion
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
4
Prevention
| Food | Other |
Exercise load and placebo
blood drawing
Exercise load and test food A (active ingredient 2.5mg)
blood drawing
Exercise load and test food B (active ingredient 10mg)
blood drawing
Exercise load and test food C (active ingredient 25mg)
blood drawing
| 20 | years-old | <= |
| 65 | years-old | > |
Male
1)Healthy subjects who are aged 20-64
2)Subjects whose maximal oxygen consumption (VO2peak) is 38 mL/kg min or less
3)Subjects who can participate in dietary interventions, intake of test foods, blood samplings, urine samplings, and maintain rest as scheduled
4)Subjects who voluntarily give written informed consent
1)Subjects whose blood test results are judged to be ineligible for this study by lead principal investigator
2)Subjects with gastrointestinal, cardiovascular, endocrine, or other disorders, or with a history of such disorders, who are judged by lead principal investigator to be ineligible for the study
3)As a rule, subjects who regularly use drugs for the treatment of diseases
4)Subjects who are judged to be ineligible for this study by lead principal investigator
21
| 1st name | Koichiro |
| Middle name | |
| Last name | Hamada |
Otsuka Pharmaceutical Co., Ltd.
Saga Nutraceuticals Research Institute
842-0195
5006-5 Yoshinogari-cho, Kanzaki-gun, Saga
+81-952-52-1522
hamadako@otsuka.jp
| 1st name | Yasutaka |
| Middle name | |
| Last name | Ikeda |
Otsuka Pharmaceutical Co., Ltd.
Saga Nutraceuticals Research Institute
842-0195
5006-5 Yoshinogari-cho, Kanzaki-gun, Saga
+81-952-52-1522
Ikeda.Yasutaka@otsuka.jp
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Self funding
The Ethics Committee of Otsuka Pharmaceutical Co., Ltd.
Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8242, Japan
+81-3-6717-1499
shimizu_se@otsuka.jp
NO
| 2022 | Year | 11 | Month | 23 | Day |
under submission
Unpublished
under submission
25
Oxygen utilization efficiency slope and VO2max significantly increased in a dose-dependent manner with a single ingestion of test food.
| 2022 | Year | 11 | Month | 22 | Day |
Healthy Volunteers
Subjects were selected based on the key inclusion and exclusion criteria
ND
Primary outcomes:
oxygen utilization efficiency slope and maximal oxygen uptake
Completed
| 2016 | Year | 04 | Month | 20 | Day |
| 2016 | Year | 04 | Month | 20 | Day |
| 2016 | Year | 05 | Month | 14 | Day |
| 2016 | Year | 10 | Month | 01 | Day |
| 2016 | Year | 10 | Month | 07 | Day |
| 2016 | Year | 10 | Month | 07 | Day |
| 2016 | Year | 12 | Month | 09 | Day |
| 2022 | Year | 11 | Month | 22 | Day |
| 2022 | Year | 11 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056425